CVN424 is an orally active and selective GPR6 inverse agonist with a K i of 9.4 nM and an EC 50 of 38 nM. CVN424 is brain-penetrant and has the potential for Parkinson disease research
In Vitro
CVN424 (Compound 6i) has 265 fold and 68 fold selectivities over GPR3 and GPR12. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
CVN424 is an orally active and selective GPR6 inverse agonist with a K i of 9.4 nM and an EC 50 of 38 nM. CVN424 is brain-penetrant and has the potential for Parkinson disease research.
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
This product requires cold chain shipping. Ground and other economy services are not available.
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.